Preferred Label : Upinitatug Rilsodotin;
NCIt synonyms : Anti-NaPi2b ADC XMT-1536; ADC XMT-1536; Anti-NaPi2b/Auristatin F-HPA ADC XMT-1536; Upifitamab Rilsodotin;
NCIt definition : A proprietary antibody-drug conjugate (ADC) composed of upinitatug , a proprietary,
humanized monoclonal antibody against human sodium-dependent phosphate transport protein
2B (SLC34A2; NaPi2b), site-specifically linked, via a protease cleavable linker, to
the proprietary cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin
F-hydroxypropylamide), with potential antineoplastic activity. Upinitatug rilsodotin
is produced via the proprietary dolaflexin ADC conjugation platform, which promotes
the conjugation of between 10 and 15 AF-HPA payload molecules to each XMT-1535 antibody.
Upon administration of upinitatug rilsodotin, the antibody moiety targets and binds
to NaPi2b expressed on tumor cells. Upon binding, internalization by endosomes/lysosomes,
and enzymatic cleavage, the AF-HPA binds to tubulin and inhibits microtubule polymerization,
which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells.
NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer
cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance
of phosphate homeostasis.;
UNII : E8US1SQ3B5;
CAS number : 2254119-00-9;
Molecule name : XMT 1536; XMT-1536;
NCI Metathesaurus CUI : CL545394;
Origin ID : C147577;
UMLS CUI : C5446322;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
